Tisagenlecleucel Suspension (Kymriah)

    loading  Checking for direct PDF access through Ovid

Abstract

Kymriah is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

Related Topics

    loading  Loading Related Articles